EGFR-targeted therapy is often used in patients with EGFR-driven cancer but is limited by on-target/off-tumor toxicities. Here, the authors develop a bispecific antibody targeting both EGFR and B7-H3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results